ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

URGN vs CMPS // RETURN ON INVESTED CAPITAL (ROIC)

UroGen Pharma Ltd. (NASDAQ) VS. COMPASS Pathways Plc American Depository Shares (NASDAQ) • 15-METRIC TALLY: URGN 1 — CMPS 3
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (URGN VS. CMPS) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC URGN CMPS SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 88.70% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) ACTIVE -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield -9.94% -9.31% -0.63 CMPS /fcf-yield <GO>
Operating Margin -60.00% — — TIE /operating-margins <GO>
Net Profit Margin -60.00% — — TIE /net-margins <GO>
Revenue Growth (YoY) 21.40% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 0.20 — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 3/9 1/9 +2.00 URGN /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 29.7 46.1 -16.40 CMPS /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $1.60B $1.60B -$2.8M CMPS /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR URGN REV CMPS REV URGN GROSS % CMPS GROSS % URGN FCF CMPS FCF
FY 2025 $109.8M $501.3M 88.7% — -$162.7M -$157.2M
FY 2024 $90.4M $499.0M 90.2% — -$97.1M -$119.2M
FY 2023 $82.7M $383.4M — — -$76.4M -$97.4M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
URGN // BETA —
CMPS // BETA —